SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I. Luttichuys who wrote (140)12/1/1996 8:55:00 PM
From: Howard Henick   of 1762
 
Funny, but Xoma is my favorite stock; even more than IMGN.

I still think IMGN's technology is worth a lot more than the market is saying; especially when compared to similar technologies like IDEC. I think the market is simply more comfortable with IDEC because it has corporate partners. Once IMGN gets corporate partners and its survival assured, watch out. After all, while Xoma and IMGN are well off their highs, all biotechs are down, including IDEC, now trading 10 points off its highs.

Good luck - Howard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News